(Reuters) - He said the company will discuss the issue with its partner, Swiss drugmaker Novartis AG . However, he said: "I do not want to raise any expectations because I believe this drug will have no future in further clinical development."
The company said the U.S. Food and Drug Administration was concerned over gastrointestinal side effects such as nausea and vomiting.
Read more at Reuters.com Hot Stocks News
The company said the U.S. Food and Drug Administration was concerned over gastrointestinal side effects such as nausea and vomiting.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment